|
I forgot to mention that my sister participated in an early Lapatinib (aka Tykerb) trial Feb-April '05, and while it did not work for her then, it was making a difference for some other patients. I would think Tykerb would be a better early systemic treatment choice for brain mets because it is targeted at Her2+bc, and is generally better tolerated.
|